Singapore markets open in 2 hours 30 minutes
Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,180.74 +52.95 (+1.03%) Dow
38,852.27 +176.59 (+0.46%) Nasdaq
16,349.25 +192.92 (+1.19%) Bitcoin USD
63,545.90 -209.41 (-0.33%) CMC Crypto 200
1,367.71 +55.08 (+4.20%)
Ligand Pharmaceuticals Incorporated (LGND)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 73.90 |
| Open | 74.05 |
| Bid | 72.60 x 100 |
| Ask | 73.08 x 100 |
| Day's range | 72.62 - 74.70 |
| 52-week range | 49.24 - 94.57 |
| Volume | |
| Avg. volume | 181,050 |
| Market cap | 1.308B |
| Beta (5Y monthly) | 0.92 |
| PE ratio (TTM) | 24.04 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 02 Jul 2010 |
| 1y target est | N/A |
- Zacks
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.
- Zacks
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.
- Zacks
Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.
© 2024 Yahoo. All rights reserved.